



## Manifesto towards a health IPCEI

Health industries before and in response to the pandemic have brought important contributions to the EU, both in terms of competitiveness and of citizens' well-being. Nevertheless, some specific areas can be subject to market failures. We highlight the success story of the common European action towards the upscale of vaccine production and welcome the numerous initiatives taken by the EU towards reinforcing the European health market and its resilience, such as the EU Pharmaceutical Strategy, the EU industrial strategy, Horizon Europe (including the Innovative Health Initiative), EU4Health, the European Health Data Space, and the Health Emergency and Response Authority (HERA). We stress more globally the importance of a streamlined regulatory framework in pushing forward innovation.

Building on these initiatives, and without overlapping or duplicating them, **Austria, Belgium, Denmark, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Romania, Slovenia and Spain commit to deepen the work towards the deployment of "Important Projects of Common European Interest" (IPCEI) to further address potential market failures impeding innovation and improve quality of, and access to, healthcare of patients.**

The common work on the Health IPCEI(s) will be targeting three main objectives. First, it will provide an important contribution to the European Health Union, the New Industrial Strategy for Europe and its update, and their respective objectives. Second, it should contribute to the first industrial deployment of fundamentally innovative production processes, in particular sustainable ones, that would be impossible without the aid granted. Third, it should foster state-of-the-art, quality, and accessible healthcare through the development of new products and services with a high research and innovation content.

The Health IPCEI(s) will contribute to an EU-wide coordinated strategy based on a clustered approach where possible. It will stimulate major innovation and bring important added value to the EU in key future strategic areas. Projects supported, within the framework of the December 2021 IPCEI guidelines, will as such address proven market failures and bring through this wide positive externalities for the whole European Union. They should be the best means to achieve our policy goals compared to alternative financial and regulatory policy response mechanisms.

Signatories will in this respect consider projects for the first wave of the IPCEI towards: **(i) innovating and greening production technologies and processes for medicines/drug products (ii) innovation in antimicrobial resistance and rare diseases, as well as in emerging health threats where complementary to HERA; and (iii) developing cell and gene therapies, including production processes and technologies.** Signatories will swiftly consider other areas to address within the second wave of the IPCEI, in particular digital health, Medtech, and medical devices.

We support the start of the process towards the deployment of Health IPCEI(s) and the initiation of its next steps in coordination with the European Commission, the EIT Health, and European industry. **Signatories, contingent on domestic budget decisions, will adhere to an inclusive work process allowing all Member States and EEA Members interested in a Health IPCEI along with all businesses, including SMEs, to progress together through the stages of the project's preparation. They invite all other Member States to join this initiative which stays opened. They will prenotify the first wave of the IPCEI for approval by the EU Commission in two linked slots, the first one in June completed with a second slot in October. Additionally, a second wave will be scheduled before the end of the year.**

**Ms. Margarete Schramböck, Federal Minister for Digital and Economic Affairs, for Austria**

**Mr. Thomas Dermine, State Secretary for Recovery, Strategic Investments and Science Policy at Federal level, along with Mrs. Hilde Crevits, Mr. Willy Borsus, and Mrs. Barbara Trachte, Ministers in Charge of Economy and Innovation at regional levels, for Belgium**

**Mr. Anders Thusgaard, Deputy Permanent Secretary, Business Affairs, on behalf of Mr. Simon Kollerup, Minister for Industry, Business, and Financial Affairs, for Denmark**

**Ms. Agnès Pannier-Runacher, Minister-Delegate for Industry, for France**

**Mr. Spyridon Adonis Georgiadis, Minister of Development and Investments, for Greece**

**Mr. Gulyas Tibor, Deputy State Secretary for Innovation, for Hungary**

**Mr. Leo Varadkar, Tánaiste and Minister for Enterprise, Trade and Employment, for Ireland**

**Mr. Giancarlo Giorgetti, Minister of Economic Development, for Italy**

**Mr. Edmunds Valantis, State Secretary of the Ministry for Economy, for Latvia**

**Ms. Aušrinė Armonaitė, Minister for the Economy and Innovation, for Lithuania**

**Mr. Franz Fayot, Minister of the Economy, for Luxembourg**

**Dr. J.A.A.M. van Diemen-Steenvoorde, Director-General Curative Care on behalf of the Ministry of Health, Welfare and Sport, for the Netherlands**

**Mr. Mariusz Jerzy Golecki, Undersecretary of State, Ministry of Economic Development and Technology, for Poland**

**Dr. Alexandru Rafila, Minister of Health, for Romania**

**Ms. Polona Rifelj, State Secretary, on behalf of Mr. Zdravko Pocivalsek, Minister of Economic Development and Technology, for Slovenia**

**Ms. Reyes Maroto Illera, Minister of Industry, Trade and Tourism, for Spain**